Exicure, inc. XCUR.US Overview
XCUR AI Analysis & Strategy
Analysis Conclusion
The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.
XCUR Current Performance
-8.41%
Exicure, inc.
0.61%
Avg of Sector
-0.03%
S&P500
XCUR Key Information
XCUR Financial Forecast
Unit : USD
XCUR Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | 20.5 | 191% | -2,257.9% | 21.77M | 928% | 458.3% | -256% |
| 2022Q2 | -5.2 | 87.2% | 15.6% | 2.02M | 154.8% | -48.3% | -302.3% |
| 2022Q1 | -8.3 | 65.4% | 591.7% | 2.47M | 3,027.8% | -39.7% | -325.5% |
| 2021Q4 | -10.51 | 50% | 400.5% | 2.57M | 157.3% | -40.3% | -652.7% |
| 2021Q3 | -22.52 | -49.9% | -11.8% | 2.12M | -13.3% | -39.5% | 640% |
XCUR Profile
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.